Steel is moving higher without screaming for attention, and that’s the tell. If you appreciate momentum backed by restraint, this setup is worth your time.

Don’t Let These Undervalued Stocks Slip Through Your Fingers!

We now send our favorite value picks via text, too, so you’ll get the same actionable news without having to open your inbox.

👉 Click here to get stock picks by text and uncover the best value opportunities!

Materials Sector

Ternium S.A. (NYSE: TX) is putting on a compelling show right now.

TX operates in the Materials sector, which tends to gain traction when industrial demand and pricing power improve, and the setup becomes more compelling.

This is not a flashy, overheated runner that already burned through its upside. It is a steel name showing steady strength while still trading at levels that value-focused strategies can appreciate.

TX has been in the news for a clear reason: it is delivering price momentum without demanding a premium valuation.

The recent move reflects growing market interest, supported by improving earnings expectations. When forecasts start moving higher, the share price often responds, and TX benefits from this setup.

Momentum That Still Makes Sense

You are seeing upward price action without the stock racing too far ahead of its fundamentals.

The trend points to confidence building gradually rather than speculative chasing.

That keeps the momentum intact while leaving room for additional upside.

Valuation Support in a Cyclical Space

Even with improving price action, TX does not require abandoning valuation discipline.

The stock remains priced in a way that signals caution instead of euphoria.

In a cyclical Materials name, that kind of foundation can help momentum last longer.

Healthcare Sector

Collegium Pharmaceutical Inc (NASDAQ: COLL) is showing up on screens for a reason, and it is not driven by hype. You are looking at a healthcare name that is gaining traction because the valuation does not line up with the business performance.

Right now, the company checks two boxes that rarely show up together.

What stands out is how restrained the pricing still looks compared to peers in the same industry.

Sales and cash flow are being valued at a noticeable discount, which gives you downside support without requiring heroic growth assumptions.

That matters in healthcare, where consistency and cash generation often drive long-term performance. The takeaway is simple. You are not chasing momentum or paying for perfection here.

Valuation That Leaves Breathing Room

COLL is priced in a way that gives you margin for error rather than demanding perfection.

The market is assigning conservative value to its sales and cash generation.

That restraint can work in your favor if execution continues to hold up.

Earnings Strength Doing the Heavy Lifting

The current setup is supported by improving earnings expectations, not just multiple compression.

You are seeing fundamentals reinforce the valuation case instead of fighting it. That alignment often creates a sturdier base for future gains.

Healthcare Sector

Cardinal Health Inc (NYSE: CAH) is quietly doing the heavy lifting of American healthcare logistics, and you should care because scales like this are harder to replicate than headlines suggest.

The company moves pharmaceuticals, manages specialty distribution, and operates radiopharmaceutical and PET networks that plug directly into hospital workflows.

That operational breadth means revenue streams come from routine, mission-critical services rather than trendy product cycles.

At a time when supply chain resilience matters as much as price, CAH’s footprint gives it leverage to defend margins and widen relationships with large health systems.

Beyond its scale, CAH is innovating in specialty drug distribution and pharmacy management, making complex processes look routine.  

That combination positions CAH to capture steady demand while quietly building long-term value for shareholders.

Operational Breadth That Matters

CAH’s platform is not a collection of unrelated businesses.

It is an integrated machine that feeds hospitals, clinics, and specialty providers every day.

That consistency tends to smooth earnings and reduce volatility for holders.

Valuation Meets Durability

You are getting exposure to a company with steady cash flow and a realistic growth runway without paying for perfection.

That balance between practical upside and downside protection explains why CAH is in the conversation now.

Sirius XM Holdings Inc (NASDAQ: SIRI) has been one of Berkshire Hathaway’s longer-term holdings, and even with a decade of underperformance, the company is setting the stage for a potential rebound.

Subscriber growth has stabilized, advertising revenue is inching higher, and cost-cutting measures are freeing up cash for strategic initiatives.

You are looking at a company trading at a bargain relative to cash flow while experimenting with ad-supported and lower-cost subscription plans to capture new customers.

If auto sales recover and the new advertising tiers gain traction, the top line could stabilize and even return to growth.

The leverage in the business means that even modest improvements could shift the stock’s valuation quickly, making SIRI one to watch this week.

Phillips 66 (NYSE: PSX) is drawing interest after dipping while the broader market climbed, giving you a potential entry point in a sector that never sleeps.

The oil refiner is on track for a big earnings reveal in early February, with estimates signaling a major jump in profitability despite slightly lower revenue.

You are looking at a company trading at a discount relative to its peers, with a low PEG ratio suggesting growth potential is underpriced.

Forward-looking trends and modest estimate revisions indicate the market is starting to take note.

With strong fundamentals, solid valuation, and a key earnings announcement around the corner, PSX is in a position to make some moves that could catch traders’ eyes this week.

Nike Inc (NYSE: NKE) has been in the spotlight as the company works to convince the market that its turnaround is real.

Shares have bounced 15% since mid-December, showing that momentum may finally be returning after a tough year.

You are seeing CEO Elliott Hill take decisive action in the U.S. and now setting his sights on China, with high-profile support from names like Tim Cook signaling confidence.

Despite mixed opinions on timing and recovery, the company is addressing operational challenges head-on while keeping its brand dominance intact.

With execution improving and markets reacting, NKE could offer traders a chance to ride a potential rebound, especially as strategic initiatives in key regions begin to show results.

That's our coverage for today; thanks for reading! Reply to this email with feedback or any [blank] stocks you want me to check out.

Best Regards,
—Noah Zelvis
Undervalued Edge